Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
MIRA Pharmaceuticals, Inc. Common Stock (MIRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: MIRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.38
1 Year Target Price $10.38
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.11% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 62.40M USD | Price to earnings Ratio - | 1Y Target Price 10.38 |
Price to earnings Ratio - | 1Y Target Price 10.38 | ||
Volume (30-day avg) 1 | Beta 1.81 | 52 Weeks Range 0.73 - 2.45 | Updated Date 12/14/2025 |
52 Weeks Range 0.73 - 2.45 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.6 |
Earnings Date
Report Date 2025-12-03 | When - | Estimate -0.09 | Actual -0.0682 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.64% | Return on Equity (TTM) -123.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58867947 | Price to Sales(TTM) - |
Enterprise Value 58867947 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.45 | Shares Outstanding 41876087 | Shares Floating 34944338 |
Shares Outstanding 41876087 | Shares Floating 34944338 | ||
Percent Insiders 16.65 | Percent Institutions 3.25 |
About MIRA Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2023-08-03 | CEO & Chairman Mr. Erez Aminov | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees - | Website https://mirapharmaceuticals.com |
Full time employees - | Website https://mirapharmaceuticals.com | ||
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.